{"id":2040,"date":"2026-05-21T15:51:22","date_gmt":"2026-05-21T20:51:22","guid":{"rendered":"https:\/\/global-pharma.com.co\/?p=2040"},"modified":"2026-06-18T14:11:54","modified_gmt":"2026-06-18T19:11:54","slug":"terapias-psicodelicas-fda","status":"publish","type":"post","link":"https:\/\/global-pharma.com.co\/es\/terapias-psicodelicas-fda\/","title":{"rendered":"FDA acelera aprobaci\u00f3n de medicamentos psicod\u00e9licos"},"content":{"rendered":"\n<h3 class=\"wp-block-heading\">La FDA implementa mecanismos de v\u00eda r\u00e1pida para investigar medicamentos psicod\u00e9licos destinados a tratar enfermedades mentales graves y resistentes.<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">La industria farmac\u00e9utica global est\u00e1 presenciando un cambio de paradigma regulatorio. Tras la orden ejecutiva emitida en abril de 2026, la FDA ha puesto en marcha mecanismos de v\u00eda r\u00e1pida para investigar medicamentos psicod\u00e9licos espec\u00edficamente <strong>agonistas de la serotonina-2A<\/strong> para tratar enfermedades mentales graves y resistentes al tratamiento tradicional.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Este movimiento, impulsado por la necesidad de soluciones contra la depresi\u00f3n mayor y el trastorno de estr\u00e9s postraum\u00e1tico (TEPT), abre una nueva categor\u00eda de activos para los laboratorios que buscan liderar en innovaci\u00f3n.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Puntos clave del anuncio:<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Vales de Prioridad Nacional:<\/strong> La FDA ha otorgado prioridad a investigaciones sobre <strong>psilocibina y metilona<\/strong>, acelerando su camino hacia la aprobaci\u00f3n cl\u00ednica.<\/li>\n\n\n\n<li><strong>El avance de la Noriboga\u00edna:<\/strong> Por primera vez, se autoriza un estudio de fase temprana para el clorhidrato de noriboga\u00edna destinado al tratamiento del alcoholismo.<\/li>\n\n\n\n<li><strong>Gu\u00edas metodol\u00f3gicas:<\/strong> La agencia publicar\u00e1 directrices estrictas sobre el dise\u00f1o de estudios y el seguimiento de pacientes, reconociendo los desaf\u00edos cient\u00edficos \u00fanicos de estas sustancias.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">\u00bfQu\u00e9 significa esto para el mercado de materias primas?<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">La apertura de la FDA no es un cheque en blanco; es un llamado a la <strong>ciencia s\u00f3lida<\/strong>. Para que estos f\u00e1rmacos pasen de la investigaci\u00f3n cl\u00ednica a la producci\u00f3n comercial, la industria requerir\u00e1:<\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li><strong>Pureza Anal\u00edtica Superior:<\/strong> Al ser sustancias que alteran la percepci\u00f3n, cualquier impureza en el API puede comprometer dr\u00e1sticamente la seguridad del paciente.<\/li>\n\n\n\n<li><strong>Rigor Regulatorio:<\/strong> La manipulaci\u00f3n de derivados de la iboga\u00edna o psilocibina exige un cumplimiento estricto de las normativas internacionales sobre sustancias controladas.<\/li>\n\n\n\n<li><strong>Log\u00edstica de Alta Seguridad:<\/strong> El transporte de estos activos requiere trazabilidad total y protocolos de seguridad que eviten cualquier desv\u00edo en la cadena de suministro.<\/li>\n<\/ol>\n\n\n\n<p class=\"wp-block-paragraph\">Fuente: <a href=\"https:\/\/consultorsalud.com\/fda-terapias-psicodelicas-enfermedades-mentales\/\">https:\/\/consultorsalud.com\/fda-terapias-psicodelicas-enfermedades-mentales\/<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n","protected":false},"excerpt":{"rendered":"<p>La FDA acelera el proceso de evaluaci\u00f3n y aprobaci\u00f3n de terapias basadas en psicod\u00e9licos, abriendo una nueva v\u00eda regulada para el tratamiento de trastornos de salud mental graves y resistentes.<\/p>\n","protected":false},"author":3,"featured_media":2065,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_joinchat":[],"footnotes":""},"categories":[6],"tags":[],"class_list":["post-2040","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-blog"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>FDA acelera aprobaci\u00f3n de medicamentos psicod\u00e9licos &#8226; Global Pharma &amp; Logistic S.A.S.<\/title>\n<meta name=\"description\" content=\"La FDA implementa mecanismos de v\u00eda r\u00e1pida para investigar medicamentos psicod\u00e9licos destinados a tratar enfermedades mentales graves y resistentes.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/global-pharma.com.co\/es\/terapias-psicodelicas-fda\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FDA acelera aprobaci\u00f3n de medicamentos psicod\u00e9licos &#8226; Global Pharma &amp; Logistic S.A.S.\" \/>\n<meta property=\"og:description\" content=\"La FDA implementa mecanismos de v\u00eda r\u00e1pida para investigar medicamentos psicod\u00e9licos destinados a tratar enfermedades mentales graves y resistentes.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/global-pharma.com.co\/es\/terapias-psicodelicas-fda\/\" \/>\n<meta property=\"og:site_name\" content=\"Global Pharma &amp; Logistic S.A.S.\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-21T20:51:22+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-18T19:11:54+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/global-pharma.com.co\/wp-content\/uploads\/2026\/05\/Presentacion-Comercial-Global-Pharma-Logistic-1.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1920\" \/>\n\t<meta property=\"og:image:height\" content=\"1080\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Mar\u00eda Camila Sanchez\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Mar\u00eda Camila Sanchez\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/global-pharma.com.co\\\/terapias-psicodelicas-fda\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/global-pharma.com.co\\\/terapias-psicodelicas-fda\\\/\"},\"author\":{\"name\":\"Mar\u00eda Camila Sanchez\",\"@id\":\"https:\\\/\\\/global-pharma.com.co\\\/#\\\/schema\\\/person\\\/912625696b849a3374bc496e1df87a7c\"},\"headline\":\"FDA acelera aprobaci\u00f3n de medicamentos psicod\u00e9licos\",\"datePublished\":\"2026-05-21T20:51:22+00:00\",\"dateModified\":\"2026-06-18T19:11:54+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/global-pharma.com.co\\\/terapias-psicodelicas-fda\\\/\"},\"wordCount\":336,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/global-pharma.com.co\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/global-pharma.com.co\\\/terapias-psicodelicas-fda\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/global-pharma.com.co\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/Presentacion-Comercial-Global-Pharma-Logistic-1.png\",\"articleSection\":[\"Blog\"],\"inLanguage\":\"es-CO\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/global-pharma.com.co\\\/terapias-psicodelicas-fda\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/global-pharma.com.co\\\/terapias-psicodelicas-fda\\\/\",\"url\":\"https:\\\/\\\/global-pharma.com.co\\\/terapias-psicodelicas-fda\\\/\",\"name\":\"FDA acelera aprobaci\u00f3n de medicamentos psicod\u00e9licos &#8226; Global Pharma &amp; Logistic S.A.S.\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/global-pharma.com.co\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/global-pharma.com.co\\\/terapias-psicodelicas-fda\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/global-pharma.com.co\\\/terapias-psicodelicas-fda\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/global-pharma.com.co\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/Presentacion-Comercial-Global-Pharma-Logistic-1.png\",\"datePublished\":\"2026-05-21T20:51:22+00:00\",\"dateModified\":\"2026-06-18T19:11:54+00:00\",\"description\":\"La FDA implementa mecanismos de v\u00eda r\u00e1pida para investigar medicamentos psicod\u00e9licos destinados a tratar enfermedades mentales graves y resistentes.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/global-pharma.com.co\\\/terapias-psicodelicas-fda\\\/#breadcrumb\"},\"inLanguage\":\"es-CO\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/global-pharma.com.co\\\/terapias-psicodelicas-fda\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es-CO\",\"@id\":\"https:\\\/\\\/global-pharma.com.co\\\/terapias-psicodelicas-fda\\\/#primaryimage\",\"url\":\"https:\\\/\\\/global-pharma.com.co\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/Presentacion-Comercial-Global-Pharma-Logistic-1.png\",\"contentUrl\":\"https:\\\/\\\/global-pharma.com.co\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/Presentacion-Comercial-Global-Pharma-Logistic-1.png\",\"width\":1920,\"height\":1080},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/global-pharma.com.co\\\/terapias-psicodelicas-fda\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Inicio\",\"item\":\"https:\\\/\\\/global-pharma.com.co\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"FDA acelera aprobaci\u00f3n de medicamentos psicod\u00e9licos\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/global-pharma.com.co\\\/#website\",\"url\":\"https:\\\/\\\/global-pharma.com.co\\\/\",\"name\":\"Distribuidor de materias primas farmac\u00e9uticas en Colombia.\",\"description\":\"Principios Activos y Materias Primas en Colombia\",\"publisher\":{\"@id\":\"https:\\\/\\\/global-pharma.com.co\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/global-pharma.com.co\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es-CO\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/global-pharma.com.co\\\/#organization\",\"name\":\"Global Pharma & Logistic S.A.S.\",\"alternateName\":\"Global Pharma & Logistic S.A.S.\",\"url\":\"https:\\\/\\\/global-pharma.com.co\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es-CO\",\"@id\":\"https:\\\/\\\/global-pharma.com.co\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/global-pharma.com.co\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/LOGO-COMPLETO2-02.jpg\",\"contentUrl\":\"https:\\\/\\\/global-pharma.com.co\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/LOGO-COMPLETO2-02.jpg\",\"width\":2133,\"height\":2133,\"caption\":\"Global Pharma & Logistic S.A.S.\"},\"image\":{\"@id\":\"https:\\\/\\\/global-pharma.com.co\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.linkedin.com\\\/company\\\/51710617\\\/admin\\\/dashboard\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/global-pharma.com.co\\\/#\\\/schema\\\/person\\\/912625696b849a3374bc496e1df87a7c\",\"name\":\"Mar\u00eda Camila Sanchez\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es-CO\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/0329561f75938cb23698a3fea3fb2b239761b6609e52728bd3aef6667c8eecb3?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/0329561f75938cb23698a3fea3fb2b239761b6609e52728bd3aef6667c8eecb3?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/0329561f75938cb23698a3fea3fb2b239761b6609e52728bd3aef6667c8eecb3?s=96&d=mm&r=g\",\"caption\":\"Mar\u00eda Camila Sanchez\"},\"url\":\"https:\\\/\\\/global-pharma.com.co\\\/es\\\/author\\\/maria-sanchez\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"FDA acelera aprobaci\u00f3n de medicamentos psicod\u00e9licos &#8226; Global Pharma &amp; Logistic S.A.S.","description":"La FDA implementa mecanismos de v\u00eda r\u00e1pida para investigar medicamentos psicod\u00e9licos destinados a tratar enfermedades mentales graves y resistentes.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/global-pharma.com.co\/es\/terapias-psicodelicas-fda\/","og_locale":"es_ES","og_type":"article","og_title":"FDA acelera aprobaci\u00f3n de medicamentos psicod\u00e9licos &#8226; Global Pharma &amp; Logistic S.A.S.","og_description":"La FDA implementa mecanismos de v\u00eda r\u00e1pida para investigar medicamentos psicod\u00e9licos destinados a tratar enfermedades mentales graves y resistentes.","og_url":"https:\/\/global-pharma.com.co\/es\/terapias-psicodelicas-fda\/","og_site_name":"Global Pharma &amp; Logistic S.A.S.","article_published_time":"2026-05-21T20:51:22+00:00","article_modified_time":"2026-06-18T19:11:54+00:00","og_image":[{"width":1920,"height":1080,"url":"https:\/\/global-pharma.com.co\/wp-content\/uploads\/2026\/05\/Presentacion-Comercial-Global-Pharma-Logistic-1.png","type":"image\/png"}],"author":"Mar\u00eda Camila Sanchez","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"Mar\u00eda Camila Sanchez","Tiempo de lectura":"2 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/global-pharma.com.co\/terapias-psicodelicas-fda\/#article","isPartOf":{"@id":"https:\/\/global-pharma.com.co\/terapias-psicodelicas-fda\/"},"author":{"name":"Mar\u00eda Camila Sanchez","@id":"https:\/\/global-pharma.com.co\/#\/schema\/person\/912625696b849a3374bc496e1df87a7c"},"headline":"FDA acelera aprobaci\u00f3n de medicamentos psicod\u00e9licos","datePublished":"2026-05-21T20:51:22+00:00","dateModified":"2026-06-18T19:11:54+00:00","mainEntityOfPage":{"@id":"https:\/\/global-pharma.com.co\/terapias-psicodelicas-fda\/"},"wordCount":336,"commentCount":0,"publisher":{"@id":"https:\/\/global-pharma.com.co\/#organization"},"image":{"@id":"https:\/\/global-pharma.com.co\/terapias-psicodelicas-fda\/#primaryimage"},"thumbnailUrl":"https:\/\/global-pharma.com.co\/wp-content\/uploads\/2026\/05\/Presentacion-Comercial-Global-Pharma-Logistic-1.png","articleSection":["Blog"],"inLanguage":"es-CO","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/global-pharma.com.co\/terapias-psicodelicas-fda\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/global-pharma.com.co\/terapias-psicodelicas-fda\/","url":"https:\/\/global-pharma.com.co\/terapias-psicodelicas-fda\/","name":"FDA acelera aprobaci\u00f3n de medicamentos psicod\u00e9licos &#8226; Global Pharma &amp; Logistic S.A.S.","isPartOf":{"@id":"https:\/\/global-pharma.com.co\/#website"},"primaryImageOfPage":{"@id":"https:\/\/global-pharma.com.co\/terapias-psicodelicas-fda\/#primaryimage"},"image":{"@id":"https:\/\/global-pharma.com.co\/terapias-psicodelicas-fda\/#primaryimage"},"thumbnailUrl":"https:\/\/global-pharma.com.co\/wp-content\/uploads\/2026\/05\/Presentacion-Comercial-Global-Pharma-Logistic-1.png","datePublished":"2026-05-21T20:51:22+00:00","dateModified":"2026-06-18T19:11:54+00:00","description":"La FDA implementa mecanismos de v\u00eda r\u00e1pida para investigar medicamentos psicod\u00e9licos destinados a tratar enfermedades mentales graves y resistentes.","breadcrumb":{"@id":"https:\/\/global-pharma.com.co\/terapias-psicodelicas-fda\/#breadcrumb"},"inLanguage":"es-CO","potentialAction":[{"@type":"ReadAction","target":["https:\/\/global-pharma.com.co\/terapias-psicodelicas-fda\/"]}]},{"@type":"ImageObject","inLanguage":"es-CO","@id":"https:\/\/global-pharma.com.co\/terapias-psicodelicas-fda\/#primaryimage","url":"https:\/\/global-pharma.com.co\/wp-content\/uploads\/2026\/05\/Presentacion-Comercial-Global-Pharma-Logistic-1.png","contentUrl":"https:\/\/global-pharma.com.co\/wp-content\/uploads\/2026\/05\/Presentacion-Comercial-Global-Pharma-Logistic-1.png","width":1920,"height":1080},{"@type":"BreadcrumbList","@id":"https:\/\/global-pharma.com.co\/terapias-psicodelicas-fda\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Inicio","item":"https:\/\/global-pharma.com.co\/"},{"@type":"ListItem","position":2,"name":"FDA acelera aprobaci\u00f3n de medicamentos psicod\u00e9licos"}]},{"@type":"WebSite","@id":"https:\/\/global-pharma.com.co\/#website","url":"https:\/\/global-pharma.com.co\/","name":"Distribuidor de materias primas farmac\u00e9uticas en Colombia.","description":"Principios Activos y Materias Primas en Colombia","publisher":{"@id":"https:\/\/global-pharma.com.co\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/global-pharma.com.co\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es-CO"},{"@type":"Organization","@id":"https:\/\/global-pharma.com.co\/#organization","name":"Global Pharma & Logistic S.A.S.","alternateName":"Global Pharma & Logistic S.A.S.","url":"https:\/\/global-pharma.com.co\/","logo":{"@type":"ImageObject","inLanguage":"es-CO","@id":"https:\/\/global-pharma.com.co\/#\/schema\/logo\/image\/","url":"https:\/\/global-pharma.com.co\/wp-content\/uploads\/2025\/08\/LOGO-COMPLETO2-02.jpg","contentUrl":"https:\/\/global-pharma.com.co\/wp-content\/uploads\/2025\/08\/LOGO-COMPLETO2-02.jpg","width":2133,"height":2133,"caption":"Global Pharma & Logistic S.A.S."},"image":{"@id":"https:\/\/global-pharma.com.co\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/51710617\/admin\/dashboard\/"]},{"@type":"Person","@id":"https:\/\/global-pharma.com.co\/#\/schema\/person\/912625696b849a3374bc496e1df87a7c","name":"Mar\u00eda Camila Sanchez","image":{"@type":"ImageObject","inLanguage":"es-CO","@id":"https:\/\/secure.gravatar.com\/avatar\/0329561f75938cb23698a3fea3fb2b239761b6609e52728bd3aef6667c8eecb3?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/0329561f75938cb23698a3fea3fb2b239761b6609e52728bd3aef6667c8eecb3?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/0329561f75938cb23698a3fea3fb2b239761b6609e52728bd3aef6667c8eecb3?s=96&d=mm&r=g","caption":"Mar\u00eda Camila Sanchez"},"url":"https:\/\/global-pharma.com.co\/es\/author\/maria-sanchez\/"}]}},"_links":{"self":[{"href":"https:\/\/global-pharma.com.co\/es\/wp-json\/wp\/v2\/posts\/2040","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/global-pharma.com.co\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/global-pharma.com.co\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/global-pharma.com.co\/es\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/global-pharma.com.co\/es\/wp-json\/wp\/v2\/comments?post=2040"}],"version-history":[{"count":5,"href":"https:\/\/global-pharma.com.co\/es\/wp-json\/wp\/v2\/posts\/2040\/revisions"}],"predecessor-version":[{"id":2150,"href":"https:\/\/global-pharma.com.co\/es\/wp-json\/wp\/v2\/posts\/2040\/revisions\/2150"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/global-pharma.com.co\/es\/wp-json\/wp\/v2\/media\/2065"}],"wp:attachment":[{"href":"https:\/\/global-pharma.com.co\/es\/wp-json\/wp\/v2\/media?parent=2040"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/global-pharma.com.co\/es\/wp-json\/wp\/v2\/categories?post=2040"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/global-pharma.com.co\/es\/wp-json\/wp\/v2\/tags?post=2040"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}